CJ, Garnick only needs one new product approval. Once bavi is approved, it will quickly expand to be used to extend lives in 18 different cancer indications, and more.
That is the compounding power of bavituximab with its universal target, PS, that could be used to treat all the solid tumor cancers, and more.
Once approved, the uses for bavi will proliferate. Dr. Garnick knows this and Peregrine’s management knows this. The anti-PS platform is on the verge of approvals for commercialization, and for treating cancer worldwide.
This is what a blockbuster looks like before it’s a blockbuster.
Bavi works: We’ve seen the trial data in NSCLC and breast cancer. This immunotherapeutic medicine is the future.
IMO
sunstar
Market Data 
Markets 
AI
